## Highlights of This Issue 2593

### SPECIAL FEATURES

#### CCR Translations

**2595** Oncolytic Virotherapy Needs Trials, Not Access Programs
Kevin J. Harrington
*See article, p. 2734*

#### Molecular Pathways

**2598** Molecular Pathways: Tumor-Derived Microvesicles and Their Interactions with Immune Cells *In Vivo*
Ferdinando Pucci and Mikael J. Pittet

#### CCR Focus

**2606** PFS: The Endpoint We Love and Love to Hate
Susan E. Bates

**2607** Overview: Progression-Free Survival as an Endpoint in Clinical Trials with Solid Tumors
Ronald L. Korn and John J. Crowley

**2613** Missing Data and Measurement Variability in Assessing Progression-Free Survival Endpoint in Randomized Clinical Trials
Rajeshwari Sridhara, Sumithra J. Mandrekar, and Lori E. Dodd

**2621** The Imaging Viewpoint: How Imaging Affects Determination of Progression-Free Survival
Daniel Carl Sullivan, Lawrence H. Schwartz, and Binsheng Zhao

**2629** The Clinical Viewpoint: Definitions, Limitations of RECIST, Practical Considerations of Measurement
Liza C. Villaruz and Mark A. Socinski

**2637** Assessment of Audit Methodologies for Bias Evaluation of Tumor Progression in Oncology Clinical Trials
Jenny J. Zhang, Lijun Zhang, Huanyu Chen, Anthony J. Murgos, Lori E. Dodd, Richard Pazdur, and Rajeshwari Sridhara

### HUMAN CANCER BIOLOGY

**2657** Aberrant BAF57 Signaling Facilitates Prometastatic Phenotypes
Sucharitha Balasubramaniam, Clay E.S. Comstock, Adam Ertel, Kwang Won Jeong, Michael R. Stalcup, Sankar Addya, Peter A. McCue, William F. Ostrander Jr, Michael A. Augello, and Karen E. Knudsen

**2668** Relapsed Classic E-Cadherin (*CDH1*)–Mutated Invasive Lobular Breast Cancer Shows a High Frequency of *HER2* (*ERBB2*) Gene Mutations

### CANCER THERAPY: PRECLINICAL

**2677** Potent Antimyeloma Activity of a Novel ERK5/CDK Inhibitor
Stela Álvarez-Fernández, Maria Jesús Ortiz-Ruiz, Tracy Parrott, Sara Zaknoum, Enrique M. Ocio, Jesús San Miguel, Francis J. Burrows, Azucena Esparis-Ogando, and Atanasio Pandiella

**2688** Concomitant BRAF and PI3K/mTOR Blockade Is Required for Effective Treatment of *BRAF*<sup>V600E</sup> Colorectal Cancer
Temozolomide-Mediated DNA Methylation in Human Myeloid Precursor Cells: Differential Involvement of Intrinsic and Extrinsic Apoptotic Pathways

Inhibition of Melanoma Growth by Small Molecules That Promote the Mitochondrial Localization of ATF2

Identification of Prognosis-Relevant Subgroups in Patients with Chemoresistant Triple-Negative Breast Cancer
Ke-Da Yu, Rui Zhu, Ming Zhan, Ángel A. Rodríguez, Wei Yang, Stephen Wong, Andreas Makris, Brian D. Lehmann, Xi Chen, Ingrid Mayer, Jennifer A. Pietenpol, Zhi-Ming Shao, W. Fraser Symmans, and Jenny C. Chang

Antiviral and Antitumor T-cell Immunity in Patients Treated with GM-CSF–Coding Oncolytic Adenovirus
Anna Kanerva, Petri Nokisalmi, Iulia Diaconu, Anmilia Koski, Vincenzo Cerullo, Ilkka Liikanen, Siri Tähtinen, Minna Oksanen, Raita Heiskanen, Salli Pesonen, Timo Joensuu, Tuomo Alanko, Kaarina Partanen, Leena Laasonen, Kalevi Kairemo, Sari Pesonen, Lotta Kangasniemi, and Akseli Hemminki

Sorafenib or Placebo with Either Gemcitabine or Capecitabine in Patients with HER-2–Negative Advanced Breast Cancer That Progressed during or after Bevacizumab

Neoadjuvant Chemotherapy with or without Zoledronic Acid in Early Breast Cancer—A Randomized Biomarker Pilot Study
Matthew C. Winter, Caroline Wilson, Stuart P. Syddall, Simon S. Cross, Alyson Evans, Christine E. Ingram, Ingrid J. Jolley, Matthew Q. Hatton, Jennifer V. Freeman, Stefano Mori, Ingunn Holden, and Robert E. Coleman

Phase I Study of the Hedgehog Pathway Inhibitor IPI-926 in Adult Patients with Solid Tumors

Molecular Profiling of Aromatase Inhibitor–Treated Postmenopausal Breast Tumors Identifies Immune-Related Correlates of Resistance
Anita K. Dunbier, Zara Ghazoui, Helen Anderson, Janine Salter, Ashutosh Nerurkar, Peter Osnin, Roger A’hern, William R. Miller, Ian E. Smith, and Mitch Dowsett

Correction: Chromosome 5q Loss in Colorectal Flat Adenomas
ABOUT THE COVER

This image is taken from a bone metastasis in a patient with stage IV relapsed invasive CDH1 mutated lobular carcinoma of the breast. The tumor was negative for ERBB2 (HER2) amplification (FISH). The targeted next generation sequencing assay used in this study found an ERBB2-GRB7 putative gene fusion that has not been previously reported. The fusion retains the kinase domain of ERBB2 (uniprot.org) which suggests that it could result in ERBB2 activation. The 17q12-21 amplicon which includes both ERBB2 and GRB7 is frequently amplified in breast cancer and preclinical studies suggest that it may be a recombination hotspot. An expression screening study has reported that GRB7 can function as an ERBB2-dependent oncogene. GRB7 encodes an adaptor protein that interacts with ERBB2 and has been shown in a preclinical study to enhance its transformative capacity and increase ERBB2 phosphorylation in fibroblasts. For details, see the article by Ross and colleagues on page 2668 of this issue.

AC icon indicates Author Choice

CME icon indicates that this article is available for continuing medical education credit at http://cme.aacrjournals.org

For more information please visit www.aacrjournals.org